Extracorporeal light-chain elimination in myeloma with simple medium cutoff membrane hemodialysis: a retrospective cohort study.
acute kidney injury
dialysis
free light chains
medium cutoff hemodialysis
multiple myeloma
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
30
03
2023
accepted:
14
08
2023
medline:
25
9
2023
pubmed:
25
9
2023
entrez:
25
9
2023
Statut:
epublish
Résumé
We determined the efficacy of free light chain (FLC) removal by regular dialysis equipment (high-flux filtration) with medium cutoff (MCO) membrane hemodialysis (HD) as an adjuvant treatment to standard chemotherapy for patients with acute kidney injury complicating multiple myeloma (MM) and its impact on further dialysis dependency. Sixty patients with acute dialysis-dependent renal failure secondary to MM were treated with MCO-HD (55 patients) or HCO (high cutoff)-HD (5 patients) as a control. FLC serum concentration, total protein, immunoglobulins, and LDH were measured throughout the dialysis therapy. The kidney function of the patients was followed up for 1 year. The median age was 69 years; 25 female and 35 male patients were enrolled. HD significantly reduced FLC kappa levels in the MCO/HCO group by 58%/84% (MCO/HCO group; FLC elimination with MCO-HD is effective, technically easy, and less cost-intensive as compared with HCO-HD. Kidney function recovery in MM patients is achievable.
Sections du résumé
Background
UNASSIGNED
We determined the efficacy of free light chain (FLC) removal by regular dialysis equipment (high-flux filtration) with medium cutoff (MCO) membrane hemodialysis (HD) as an adjuvant treatment to standard chemotherapy for patients with acute kidney injury complicating multiple myeloma (MM) and its impact on further dialysis dependency.
Methods
UNASSIGNED
Sixty patients with acute dialysis-dependent renal failure secondary to MM were treated with MCO-HD (55 patients) or HCO (high cutoff)-HD (5 patients) as a control. FLC serum concentration, total protein, immunoglobulins, and LDH were measured throughout the dialysis therapy. The kidney function of the patients was followed up for 1 year.
Results
UNASSIGNED
The median age was 69 years; 25 female and 35 male patients were enrolled. HD significantly reduced FLC kappa levels in the MCO/HCO group by 58%/84% (MCO/HCO group;
Conclusion
UNASSIGNED
FLC elimination with MCO-HD is effective, technically easy, and less cost-intensive as compared with HCO-HD. Kidney function recovery in MM patients is achievable.
Identifiants
pubmed: 37746285
doi: 10.3389/fonc.2023.1193504
pmc: PMC10514899
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1193504Informations de copyright
Copyright © 2023 Schaaf, Braunisch, Holzmann-Littig, Pfister, Hannemann, Hausinger, Verbeek, Schmaderer, Renders, Heemann and Küchle.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Am Soc Nephrol. 2007 Mar;18(3):886-95
pubmed: 17229909
Ann Intern Med. 2005 Dec 6;143(11):777-84
pubmed: 16330788
J Clin Oncol. 2010 Nov 20;28(33):4976-84
pubmed: 20956629
Clin Kidney J. 2023 Feb 01;16(6):1014-1021
pubmed: 37260999
Kidney Int. 1989 Dec;36(6):1050-60
pubmed: 2601255
Clin J Am Soc Nephrol. 2009 Apr;4(4):745-54
pubmed: 19339414
PLoS One. 2016 May 06;11(5):e0154993
pubmed: 27152520
Kidney Int. 2021 Mar;99(3):570-580
pubmed: 33440212
Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1753-1754
pubmed: 30348812
Nephrol Dial Transplant. 2010 Feb;25(2):419-26
pubmed: 19767634
Sci Rep. 2015 Dec 16;5:18448
pubmed: 26669756
J Clin Invest. 1992 Feb;89(2):630-9
pubmed: 1737851
Am J Hematol. 2015 Jul;90(7):647-52
pubmed: 25858483
ScientificWorldJournal. 2011 Mar 22;11:726-35
pubmed: 21442150
NDT Plus. 2008 Apr;1(2):106-108
pubmed: 28657037
J Am Soc Nephrol. 2011 Jun;22(6):1129-36
pubmed: 21511832
PLoS One. 2016 Jul 28;11(7):e0159942
pubmed: 27467401
BMC Nephrol. 2018 Oct 4;19(1):250
pubmed: 30286730
Ann Hematol. 2012 May;91(5):729-735
pubmed: 22170517
Nephrol Dial Transplant. 2012 Oct;27(10):3823-8
pubmed: 22273664
Nat Rev Nephrol. 2011 Nov 01;8(1):43-51
pubmed: 22045243
Lancet Haematol. 2019 Apr;6(4):e217-e228
pubmed: 30872075
Eur J Haematol. 2000 Sep;65(3):175-81
pubmed: 11007053
Nephrol Dial Transplant. 2021 Feb 20;36(3):482-490
pubmed: 31773154
Kidney Int. 2008 Jun;73(11):1282-8
pubmed: 18385667
J Clin Oncol. 2016 May 1;34(13):1544-57
pubmed: 26976420
JAMA. 2017 Dec 5;318(21):2099-2110
pubmed: 29209721